Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study

OBJECTIVES: To explore the safety and efficacy of filgotinib (FIL), a Janus kinase 1 inhibitor, and lanraplenib (LANRA), a spleen kinase inhibitor, in cutaneous lupus erythematosus (CLE). METHODS: This was a phase 2, randomized, double-blind, placebo-controlled, exploratory, proof-of-concept study o...

Descripción completa

Detalles Bibliográficos
Autores principales: Werth, Victoria P, Fleischmann, Roy, Robern, Michael, Touma, Zahi, Tiamiyu, Iyabode, Gurtovaya, Oksana, Pechonkina, Alena, Mozaffarian, Afsaneh, Downie, Bryan, Matzkies, Franziska, Wallace, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157055/
https://www.ncbi.nlm.nih.gov/pubmed/34498056
http://dx.doi.org/10.1093/rheumatology/keab685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157055/
https://www.ncbi.nlm.nih.gov/pubmed/34498056
http://dx.doi.org/10.1093/rheumatology/keab685

Ejemplares similares